Treatment of Advanced or Metastatic NSCLC with KRAS G12C Mutation

This protocol covers the management of patients with advanced or metastatic non-small cell lung cancer (NSCLC) in whom a KRAS G12C mutation has been identified — a molecularly defined subgroup with a specific recommended treatment pathway.

KRAS G12C is an activating mutation that results in activation of downstream oncogenic pathways. Approximately 25% of patients with adenocarcinomas in a North American population have a KRAS mutation, making molecular testing at diagnosis critical for identifying candidates for this protocol.

Therapeutic Approach

For patients with advanced NSCLC harbouring a KRAS G12C mutation who experience disease progression after first-line systemic therapy, specific targeted therapy options are recommended as subsequent treatment. The full protocol — including which agents apply and under what circumstances — is available via the structured regimen below.

Instant Access to Structured Evidence-Based Regimens

References

KRAS G12C is an activating mutation that results in activation of downstream oncogenic pathways.
Data suggest that approximately 25% of patients with adenocarcinomas in a North American population have a KRAS mutation.
The Panel recommends adagrasib or sotorasib as subsequent therapy options for patients who experience disease progression after treatment with first-line systemic therapy.

View source ↗